SSG
MLTX icon

Summit Securities Group’s MoonLake Immunotherapeutics MLTX Stock Holding History

Summit Securities Group’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.62K Buy
+516
New +$8.55K ﹤0.01% 677
2024
Q4 		– Sell
-90
Closed -$5K – 804
2024
Q3 		$5K Buy
+90
New +$4.22K ﹤0.01% 426

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Summit Securities Group's MLTX Position: Q1 2026 in Review

Summit Securities Group opened a new position in MoonLake Immunotherapeutics (MLTX) in Q1 2026: 516 shares worth $9.62K. The stake represents ﹤0.01% of the portfolio and ranks #677 among its holdings. This is a return to the name: Summit Securities Group previously reported a position in MLTX as recently as Q3 2024.

Summit Securities Group first reported a position in MLTX in Q3 2024 and has held it in 2 quarters since. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

  • Summit Securities Group held 516 shares of MoonLake Immunotherapeutics worth $9.62K as of Q1 2026.
  • MoonLake Immunotherapeutics was a new Summit Securities Group position in Q1 2026.
  • MoonLake Immunotherapeutics made up ﹤0.01% of Summit Securities Group's portfolio in Q1 2026, its #677 holding.
  • Summit Securities Group first reported a position in MoonLake Immunotherapeutics in Q3 2024 and has held it in 2 quarters since.
  • 147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Summit Securities Group's 13F filing for Q1 2026, filed 30 Apr 2026.